newsfilter
← Latest News
GlobeNewswire·

Immutep Quarterly Activities Report Q4 FY25

Media Release The pivotal TACTI-004 Phase III trial in first line non-small cell lung cancer (1L NSCLC) continues to build momentum and is recruiting patients at a growing number of activated clinical sites and